Navigation Links
Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends
Date:2/7/2013

Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans. The findings, publishing online on February 7th in the Cell Press journal Cell Reports, suggest that sunitinib does not cause lingering risks for patients after their treatment ends.

"We were able to demonstrate that this applied across all patients and that those who had the greatest benefit from the drug while it was administered retained this benefit," says senior author Dr. Tito Fojo, of the National Cancer Institute at the National Institutes of Health.

Sunitinib, which is approved around the world for the treatment of several different cancers, works by targeting proteins on the blood vessels that feed tumors. Animal studies have suggested that treatment with sunitinib may induce changes in tumor vessels or adaptations within tumors themselves that could promote cancer growth and spread.

When Dr. Fojo and his colleagues analyzed more than 10,000 data points from the pivotal randomized phase 3 clinical trial that led to sunitinib's approval, the evidence clearly showed that no matter how long patients took sunitinib, it was not harmful, did not accelerate tumor growth, and did not shorten survival after treatment ended. During treatment, the drug slowed tumor growth and prolonged the patients' survival.

"Last year, I was approached by two patients who had grave concerns about taking sunitinib due to an article conducted in animals. I realized that if clinical data exist that refute basic science, they must be published," recalls Dr. Fojo.

The researchers' findings indicate that sunitinib can benefit patients without altering tumor biology after the drug is stopped. "We hope this can be ge
'/>"/>

Contact: Mary Beth OLeary
moleary@cell.com
617-397-2802
Cell Press
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Potential new technique for anticancer radiotherapy could provide alternative to brachytherapy
2. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
3. Enzyme accelerates malignant stem cell cloning in chronic myeloid leukemia
4. Fat Loss 4 Idiots: Review Examining New "Accelerated Fat Loss Diet" Released By DietsAndFitnessGuides.com
5. EzW2 Software From Halfpricesoft.com Updated To Accelerate Tax Reporting For Startups
6. Studying marrow, URMC researchers accelerate blood stem cells
7. Topical simvastatin shown to accelerate wound healing in diabetes
8. Concussions and head impacts may accelerate brain aging
9. Accelerated resolution therapy significantly reduces PTSD symptoms, researchers report
10. Higher energies for laser-accelerated particles possible
11. Accelerated radiation treatment effective for noninvasive breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends
(Date:7/1/2015)... York, NY (PRWEB) , ... July 01, 2015 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – today announced that they will welcome four new members to their ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... a new extraction plant for Linablue®, Spirulina-derived natural blue food coloring. Construction of ... the DIC Group’s U.S. Spirulina* production base, began in May 2014. After commissioning, ...
(Date:7/1/2015)... ... July 01, 2015 , ... OncLive® ... Hospital Corporation of America (HCA), as it further expands its Strategic Alliance Partnership ... , With this new partnership, OncLive’s editorial and marketing teams will collaborate with ...
(Date:7/1/2015)... ... July 01, 2015 , ... The 28th annual Charity Horse Show ... July 11, 2015, at 6 p.m. in Pugh Bourne Park, 343 Oakfield Road. The ... a petting zoo, an Elvis impersonator, a silent auction and concessions. , Horses and ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... lead author Lisa Stolzenberg, a Professor in FIU’s School of International and Public ... to 17 years who participated in the National Survey on Drug Use and ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2
... Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a ... Drug Application (NDA) for oxybutynin,chloride topical gel (OTG), ... Food,and Drug Administration (FDA). Watson is seeking marketing ... for the treatment of,overactive bladder (OAB)., OTG ...
... Be Medically Necessary, March of Dimes Says, WHITE ... all of the increase in U.S. singleton preterm births,according ... data., Between 1996 and 2004 there was an ... of those infants were delivered by a cesarean,section, (c-section), ...
... Attorney General Michael,B. Mukasey will deliver the keynote address ... remarks on Justice,Department nationwide efforts to combat healthcare fraud ... on WEDNESDAY, MAY 28, 2008., WHO: Attorney General ... WEDNESDAY, MAY 28, 2008, 1:00 P.M. EDT, ...
... a Tucson, Arizona,based medical device company, announced today ... $1.65 million. The financing has been,provided by Mesa ... San,Diego, Phoenix and Washington D.C., Medipacs Inc. ... with,the tremendous response by interested investors in our ...
... avoid the routine use of antioxidant supplements during radiation ... benefits of therapy, researchers concluded in a commentary published ... National Cancer Institute . , Radiation and many chemotherapy ... that damage DNA and proteins. Therefore, there is a ...
... uncovered a completely unexpected way that the brain repairs nerve ... to nearby neurons. , Astrocytes are a type of support ... their roles is to chew up damaged nerves during brain ... , Roger Chung and colleagues have now found that ...
Cached Medicine News:Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 2Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 3Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 4Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 5Health News:C-Sections a Critical Factor in Preterm Birth Increase 2Health News:Antioxidant supplements may lessen benefit of radiation and chemotherapy 2
(Date:7/1/2015)... 2015 According to a new ... Product (Natural & Synthetic, Fibrin, Collagen, Gelatin, Cyanoacrylate, Polymeric, ... Global Forecast to 2020", published by MarketsandMarkets, the global ... $2.64 Billion by 2020, growing at a CAGR of ... Browse 119 market T ables and ...
(Date:7/1/2015)... 24, 2015 Research ... of the "2015 Strategies in the Home/Self ... This new 175-page report provides analysis of ... (strips and meters), pregnancy, ovulation, and occult blood. ... requirements, technologies, and competitive profiles. The ...
(Date:7/1/2015)... FT LAUDERDALE, Florida , July 1, 2015 /PRNewswire/ ... manufacturer and marketer of innovative medical devices for the treatment ... it prevailed in a final opposition appeal hearing in the ... 482 - STENT HAVING HELICAL ELEMENTS (,482). The ,482 patent ... and has been upheld as a valid patent in amended ...
Breaking Medicine Technology:Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 2Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 3Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 42015 Strategies in the Home/Self Testing Market 2OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation 2
... Inc., (OTC Bulletin Board: NWCI ) a ... the second quarter ended June 30, 2010. More details ... 10-Q, filed with the Securities and Exchange Commission. ... made tremendous progress in commercializing our initial solution, QTinno™," ...
... Colo., Aug. 13 Mesa Laboratories, Inc. (Nasdaq: ... Directors has declared a regular quarterly cash dividend of ... September 15, 2010 to shareholders of record at the ... Mesa Laboratories develops, acquires, manufactures and markets electronic instruments ...
Cached Medicine Technology:NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 2NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 3NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 4NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 5NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 6NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 7NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 8NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 9NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 10
The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
... used for in or out-of-office screenings and for ... from 20/15 to 20/200, two rows of spatial ... driver's scene. , ,The test is very useful ... acuity score, a functional acuity score and a ...
... face is the most widely used contrast sensitivity ... four (4) rows of sine-wave gratings. At the ... these gratings test the spatial frequencies of 3, ... a full contrast sensitivity curve, which is very ...
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
Medicine Products: